News

Laga assisted a syndicate of Belgian and international investors with an investment in Syndesi Therapeutics NV

Taking on your challenges

5 February 2018

Laga assisted a syndicate of Belgian and international investors with their EUR 17 million investment in Syndesi Therapeutics NV. The investor syndicate was led by Novo Seeds and Fountain Healthcare, together with Johnson & Johnson Innovation – JJDC, Inc. (JJDC), V-BIO Ventures, the Walloon Investment Fund (SRIW) and VIVES Louvain Technology Fund.

Syndesi Therapeutics NV is a partnership between UCB and the aforementioned syndicate, based in Belgium and aimed at developing novel therapeutics for cognitive disorders by leveraging UCB’s neurology expertise in modulating the synaptic vesicle protein SV2A.

The Laga team from the Corporate - M&A practice was led by Christoph Michiels with the assistance of Vincent Schoeters.

Read the deal’s coverage

 

Did you find this useful?